Resultado da Busca
21 de mai. de 2024 · May 4, 2023 Long covid mechanisms, risk factors, and recovery: From cells to society Persistent coronavirus disease 2019 (covid-19) symptoms are increasingly well-reported in the literature.
22 de mai. de 2024 · Recently, a new revolutionary class of drugs (incretins) became available that cause obese patients to lose safely as much as 25% of their body weight with huge secondary benefits. , , , On November 7, 2023, the Food and Drug administration approved tirzepatide (Mounjaro) for the treatment of overweight and obesity.
Há 3 dias · Original Article. May 25, 2024. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. K.A. Mayer and Others DOI:10.1056/NEJMoa2400763. Correspondence. May 24, 2024. FREE. Cow’s...
24 de mai. de 2024 · Journal of the American Medical Informatics Association, ocad245, https://doi.org/10.1093/jamia/ocad245 Published: 18 December 2023 Section: Brief Communications
9 de mai. de 2024 · D. AletahaN Engl J Med 2023;389:1328-1329. Clinicians may have an ambivalent attitude about polymyalgia rheumatica, a disabling disease marked by severe muscle pain and stiffness. On the one hand ...
Há 2 dias · Thank You: 2023 JAMDA Scientific Reviewers Opens in new window. Podcast. In this episode, host Dr. Karl Steinberg, MD, HMDC, CMD, and co-editors-in-chief Barbara Resnick, PhD, CRNP, and Paul Katz, MD, CMD, will discuss three articles from the March issue.
15 de mai. de 2024 · Y. Hu and OthersN Engl J Med 2024;390:1467-1480. Of 10 patients with relapsed or refractory hematologic cancers who received sequential CAR T-cell infusion followed by allogeneic stem-cell ...
